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Introduction
Heart failure (HF) affects more than 30 million individuals worldwide and its prevalence is rising 1 .
HF-associated morbidity and mortality remain high despite therapeutic advances, with five-year survival averaging ~50% 5 . HF is a clinical syndrome defined by fluid congestion and exercise intolerance due to cardiac dysfunction 6 . HF results typically from myocardial disease with impairment of left ventricular (LV) function manifesting with either reduced or preserved ejection fraction. Several cardiovascular and systemic disorders are implicated as aetiological factors, most notably coronary artery disease (CAD), obesity and hypertension; multiple risk factors frequently cooccur and the contribution to aetiology has been challenging based on observational data alone 7, 8 .
Monogenic hypertrophic and dilated cardiomyopathy (DCM) syndromes are known causes of HF, although they account for a small proportion of disease burden 9 . HF is a complex disorder with an estimated heritability of ~26% 2 . Previous modest-sized genome-wide association studies (GWAS) of HF reported two loci, while studies of DCM have identified a few replicated loci [10] [11] [12] [13] [14] . We hypothesised that a GWAS of HF with greater power would provide an opportunity for: (i) discovery of genetic variants modifying disease susceptibility in a range of comorbid contexts, both through subtype-specific and shared pathophysiological mechanisms, such as fluid congestion; and (ii) provide insights into aetiology by estimating the unconfounded causal contribution of observationally associated risk factors by Mendelian randomisation analysis 15 .
Results
We conducted a large-scale GWAS comprising 47,309 cases and 930,014 controls of European ancestry across 26 studies from the The Heart Failure Molecular Epidemiology for Therapeutic Targets (HERMES) Consortium. Genotype data were imputed to either the 1000 Genomes Project (60%), Haplotype Reference Consortium (35%) or study-specific reference panels (5%). We performed a fixed-effect inverse variance-weighted meta-analysis relating 8,281,262 common and low-frequency variants (minor allele frequency > 1%) to HF risk (Figure 1) . We identified 12 independent genetic variants, at 11 loci associated with HF at genome-wide significance (P < 5 x 10 -8 ), including 10 loci not previously reported for heart failure (Figure 2 , Table 1 ). The quantilequantile, regional association plots and study-specific effects for each independent variant are shown in Supplementary Figures 1-3 . We replicated two previously-reported associations for HF and three of four loci for DCM (Bonferroni-corrected P < 0.05) ( Supplementary Table 1 ). Using linkage disequilibrium score regression (LDSC) 16 , we estimated the heritability of HF in UK Biobank (h 2 g) on the liability scale, as 0.088 (standard error (SE) = 0.013), based on an estimated disease prevalence of 2.5% 17 . Next, we investigated associations between the identified loci and other traits that may provide insights into aetiology. First, we queried the NHGRI-EBI GWAS Catalog 18 and a large database of genetic associations in UK Biobank (http://www.nealelab.is/uk-biobank), and identified several biomarker and disease associations at each locus ( Supplementary Tables 2-3 ). Second, we tested for associations of identified loci with ten known HF risk factors, including cardiac structure and function measures, using GWAS summary data ( Supplementary Table 4 ) [19] [20] [21] [22] [23] [24] [25] [26] . Six sentinel variants were also associated with CAD, including established loci such as CDKN2B-AS1 (9p21) and LPA 21 .
GWAS meta-analysis
Characterisation of HF loci Secondary analyses
Four variants were associated with atrial fibrillation (AF), a common antecedent and sequela of HF 27 . To estimate whether the HF risk effects were mediated wholly or in part by risk factors upstream of HF (e.g. CAD), we conditioned HF GWAS summary statistics on nine HF risk factors using mtCOJO 28 ( Supplementary Table 5 ). Conditioning on AF attenuated the HF risk effect by > 50% for the PITX2 / FAM241A locus but not other AF-associated loci (KLHL3, SYNPOL2 / AGAP5), conditioning on CAD fully attenuated effects for two of the six CAD loci (LPA, CDKN2B-AS1) and
conditioning on BMI ablated the effect of the FTO locus ( Supplementary Figure 4 and Supplementary Table 5 ). Next we performed hierarchical agglomerative clustering of loci based on cross-trait associations to identify groups related to HF subtypes (Figure 3) . Among HF loci not associated with CAD, a group of four clustered together, of which two (KLHL3 and SYNPO2L / AGAP5) were associated with AF and two (BAG3 and CDKN1A) with reduced LV systolic function (fractional shortening) (Bonferroni-corrected P < 0.05); we highlight the results for these loci in our reporting of subsequent analyses to identify candidate genes. Notably, genetic associations with DCM at the BAG3 locus have been reported previously 13, 14 .
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Figure 3. Associations of HF risk variants with traits relating to disease subtypes and risk factors. This bubble plot shows associations between the identified HF loci and risk
factors and quantitative imaging traits, using summary estimates from UK Biobank (DCM, dilated cardiomyopathy) and published GWAS summary statistics. Number in bracket represents sample size (for quantitative traits) or number of cases (for binary traits) used to derive the GWAS summary statistics. The size of the bubble represents the absolute Z score for each trait, with the direction oriented towards the HF risk allele. Red / blue indicates a positive / negative cross-trait association (i.e. increase / decrease in disease risk or increase / decrease in continuous trait). We accounted for family-wise error rate at 0.05 by Bonferroni correction for the 10 traits tested per HF locus (P < 4.5e -4 ); traits meeting this threshold of significance for association are indicated by dark colour shading. Agglomerative hierarchical clustering of variants was performed using the complete linkage method, based on Euclidian distance. Where a sentinel variant was not available for all traits, a common proxy was selected (bold text). For the LPA locus, associations for the more common of the two variants at this locus are shown. Bold text represents variants whose estimates are plotted, upon which we performed hierarchical agglomerative clustering using the complete linkage method based on Euclidian distance. Abbreviations: FS, fractional shortening; LVD, left ventricular dimension; DCM, dilated cardiomyopathy; AF, atrial fibrillation;
CAD, coronary artery disease; LDL-C, low density lipoprotein cholesterol; T2D, type 2 diabetes; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure.
We performed gene-based association analyses using MAGMA 29 to identify tissues and aetiological pathways relevant to HF. Thirteen genes were associated with HF at genome-wide significance, of which four were located within 1Mb of a sentinel HF variant and expressed in heart tissue (Supplementary Table 6 ). Tissue specificity analysis across 53 tissue types from the Genotype Tissue Expression (GTEx) project identified the atrial appendage as the highest ranked tissue for gene expression enrichment excluding reproductive organs (Supplementary Figure 5) . We sought to map candidate genes to the HF loci by assessing the functional consequences of sentinel variants (or their proxies) on gene expression, and protein structure/abundance using quantitative trait locus (QTL) analyses. Given enrichment for gene expression of HF-associated genes in the atrial appendage, we prioritised heart tissues for mapping studies, including QTL analysis.
Since the identified HF variants were located in non-coding regions, we investigated if sentinel variants were in linkage disequilibrium (LD, r 2 > 0.8) with non-synonymous variants with predicted deleterious effects. We identified a missense variant in BAG3 (rs2234962; r 2 = 0.99 with sentinel variant rs17617337) associated previously with DCM and progression to HF, and three missense variants in SYNPO2L (rs34163229, rs3812629, rs60632610; all r 2 > 0.9 with sentinel variant rs4746140) 13, 14, 30 . All 4 missense variants had Combined Annotation Dependent Depletion scores >20 suggesting deleterious effects ( Supplementary Table 7 ).
Given the enrichment of genes expressed in heart tissue from the MAGMA analysis, we examined the effects of HF variants on cis gene expression in LV, left atrium and right atrium auricular region tissues, using data from the Myocardial Applied Genomics Network (MAGNet) and Genotype-Tissue Expression (GTEx) project. Three of 12 variants were significantly associated with the expression of one or more genes located in cis in at least one heart tissue (Bonferroni-corrected P < 0.05) ( Supplementary Table 8 ). Given the modest sample sizes of myocardial eQTL studies, we also investigated a large whole blood eQTL dataset (eQTLGen consortium, n = 31,684) and found associations with cis gene expression (P < 5x10 -8 ) for 8 of 12 sentinel variants ( Supplementary   Table 9 ) 31 . For most HF variants, heart eQTL associations were consistent with those for blood traits; however, for intronic HF sentinel variants in BAG3, CDKN1A and KLHL3 we detected expression of the corresponding gene transcripts in blood only.
Next, to prioritise among candidate genes identified through eQTL associations, we estimated the posterior probability for a common causal variant underlying associations with gene expression and HF at each locus, by conducting pairwise Bayesian colocalization analysis 32 . We found evidence for colocalization (posterior probability > 0.7) for MYOZ1 and SYNPO2L in heart, PSRC1 and ABO in heart and blood; and CDKN1A in blood ( Supplementary Tables 8 and 9 ). PSRC1 and MYOZ1
were also implicated in a transcriptome-wide association analysis performed using predicted gene expression based on GTEx human atrial and ventricular expression reference data ( Supplementary Table 10 ). Using serum protein QTL data from the INTERVAL study (N = 3,301), we also identified significant concordant cis associations for BAG3 and ABO (Supplementary The HF sentinel variant at the BAG3 locus was in high LD with a non-synonymous variant associated previously with DCM, 14 and was associated with decreased cis gene expression in blood. BAG3 encodes a Z-disc-associated protein that mediates selective macroautophagy and promotes cell survival through interaction with apoptosis regulator BCL2 37 . CDKN1A encodes p21, a potent cell cycle inhibitor that mediates post-natal cardiomyocyte cell-cycle arrest 38 and is implicated in LMNA-mediated cellular stress responses 39 . KLHL3 is a negative regulator of the thiazidesensitive Na + Clcotransporter (SLC12A3) in the distal nephron; loss of function variants cause familial hyperkalaemic hypertension (FHHt) by increasing constitutive sodium and chloride resorption 40 . The sentinel variant at this locus was associated with decreased gene expression and could predispose to sodium and fluid retention. Notably, thiazide diuretics inhibit SLC12A3 to restore sodium and potassium homeostasis in FHHt and are effective treatments for preventing hypertensive HF 41 .
Although many risk factors are associated with HF, only myocardial infarction and hypertension have an established causal role in randomised controlled trials (RCTs) 42 . Important questions remain about causality for other risk factors. For instance, type 2 diabetes (T2D) is a risk factor for HF, yet it is unclear if the association is mediated via CAD risk or by direct myocardial effects, which may have important preventative implications 43 . Accordingly, we investigated potential causal roles for modifiable HF risk factors using GWAS summary data. First, we estimated the genetic correlation (rg) between HF and 11 related traits using bivariate LDSC. For eight of the eleven traits tested, we found evidence of shared additive genetic effects with estimates of rg ranging from -0.25 to 0.67 ( Supplementary Table 13 ). The estimated CAD-HF rg was 0.67, suggesting 45% (rg 2 ) of variation in genetic risk of HF is accounted for by common genetic variation shared with CAD, and that the remaining genetic variation is independent of CAD.
Next, we estimated the causal effects of the eleven HF risk factors using Generalised Summarydata-based Mendelian Randomisation, which accounts for pleiotropy by excluding heterogenous variants based on the HEIDI test (Online Methods, Supplementary Figure 6 , Supplementary   Table 14 ). Consistent with evidence from RCTs, we found evidence for causal effects of higher diastolic blood pressure (OR = 1.30 per 10 mmHg, P = 9.13 x 10 -21 ) and systolic blood pressure (OR = 1.18 per 10 mmHg, P = 4.8 x 10 -23 ), and higher risk of CAD (OR = 1.36, P = 1.67 x 10 -70 ) on HF. We found a standard deviation increment of body mass index (BMI) (equivalent to 4.4 kg/m 2
[men] -5.4 kg/m 2 [women] 44 ) accounted for a 74% higher HF risk (P = 2.67 x 10 -50 ), consistent with previous reports 45, 46 . We identified evidence supporting causal effects of genetic liability to AF (OR of HF per 1 log odds higher AF = 1.19 , P = 1.40 x 10 -75 ) and T2D (OR of HF per 1 log odds higher T2D = 1.05, P = 6.35 x 10 -05 ) and risk of HF. We did not find supportive evidence for a causal role for higher heart rate or lower glomerular filtration rate despite reported observational associations 47, 48 .
To investigate whether risk factor effects on HF were mediated by CAD and AF, we performed analyses conditioning for CAD and AF using mtCOJO. We observed attenuation of the effect of T2D after conditioning for CAD (OR = 1.02, P = 0.19), suggesting at least partial mediation by CAD risk rather than through direct myocardial effects of hyperglycaemia. Similarly, the effects of low density lipoprotein cholesterol (LDL-C) were fully explained by effects of CAD on HF risk (OR = 1.00, P = 0.80). Conversely, the effects of blood pressure, BMI, and triglycerides were only partially attenuated, suggesting causal mechanisms independent of those associated with AF and CAD (Figure 4, Supplementary Table 14 ). We identify 12 independent variant associations for HF risk at 11 genomic loci by leveraging genome-wide data on 47,309 cases and 930,014 controls, including 10 loci not previously associated with HF. The identified loci were associated with modifiable risk factors and traits related to LV structure and function. Conditioning for CAD, AF and blood pressure traits demonstrated that the effects of some loci (e.g. CDKN2B-AS1 or 9p21) were mediated wholly via risk factor trait associations (e.g. CAD); however, for 8 of 12 variants the attenuation of effects was <50% suggesting alternative mechanisms may be important. Those loci associated with reduced LV systolic function or AF mapped to candidate genes implicated in processes of cardiac development, protein homeostasis, and cellular senescence. We use genetic causal inference and conditional analysis to explore the syndromic heterogeneity and causal biology of HF and provide new insights into aetiology. Mendelian randomisation analysis confirms previously reported casual effects for BMI and provides new evidence supporting the causal role of several observationally-linked risk factors including AF, elevated blood pressure (DBP and SBP), LDL-C, CAD, triglycerides, and T2D. Using conditional analysis we demonstrate CAD-independent effects for AF, BMI, blood pressure, and estimate that the effects of T2D are mostly mediated by an increased risk of CAD.
The heterogeneity of aetiology and clinical manifestation of heart failure are likely to have reduced statistical power. We identify a modest number of genetic associations for HF compared to other cardiovascular disease GWAS of comparable sample size, such as for AF, suggesting that an important component of HF heritability may be more attributable to specific disease subtypes than components of a final common pathway 49 . Subsequent studies will explore emerging opportunities to define HF subtypes and longitudinal phenotypes in large biobanks and patient registries at scale using standardised definitions based on diagnostic codes, imaging and electronic health records.
We speculate that future analysis of HF subtypes may yield additional insights into the genetic architecture of HF to inform new approaches to prevention and treatment.
Online Methods
Samples. Participants of European ancestry from 26 cohorts (with a total of 29 distinct datasets)
with either a case-control or population-based study design were included in the meta-analysis, as part of the Heart Failure Molecular Epidemiology for Therapeutic Targets (HERMES) Consortium.
Cases included participants with a clinical diagnosis of heart failure of any aetiology with no inclusion criteria based on left ventricular ejection fraction; controls were participants without HF.
Definitions used to adjudicate heart failure status within each study are detailed in the Supplementary Table 15 and baseline characteristics for each study are provided in Supplementary Table 16 . We meta-analysed data from a total of 47,309 cases and 930,014
controls. All included studies were ethically approved by local institutional review boards and all participants provided written informed consent.
Genotyping and imputation.
All studies used high-density genotyping arrays and performed genotype calling and pre-imputation quality control (QC) as reported in Supplementary Table 17 .
Studies performed imputation using one or more of the following reference panels: 1000 Genomes Supplementary Table 17 .
Quality control on study summary-level data. Quality control of summary-level results for each study was performed according to the protocol described in Winkler et al. 16 . In brief, we used the EasyQC tool to harmonise variant IDs and alleles across studies and to compare reported allele frequencies with allele frequencies in individuals of European ancestry from the 1000 Genomes imputation reference panel 17 . We inspected P-Z plots (reported P value against P value derived from the Z score), beta and standard error distributions, and Manhattan plots to check for consistency and to identify spurious associations. For each study, variants were removed if they satisfied any one of the following criteria: imputation quality < 0.5, minor allele frequency < 0.01, absolute betas and standard errors > 10. Specific quality control measures were applied to two studies where genotyping of cases and controls was performed on different platforms, as described in Sinnott et al. 18 and Johnson et al. 19 . To check for study-level genomic inflation, we examined quantile-quantile plots and calculated the genomic inflation factor (lGC). For three studies where some degree of genomic inflation was observed (lGC > 1.1), genomic control correction was applied ( Supplementary Table 17 ) 20 .
Meta-analysis.
Meta-analysis of summary data was conducted using the fixed-effect inversevariance weighted approach implemented in METAL (released March 25 2011) 21 . Variants were included if they were present in at least half of all studies. We tested for inflation of the metaanalysis test statistic due to cryptic population structure by estimating the linkage disequilibrium score regression (LDSC) intercept, implemented using LDSC v1.0.0 22 As the LD score regression intercept indicated no inflation (LD score intercept of 1.0069), no further correction was applied to the meta-analysis summary estimates. To identify variants independently associated with HF, we analysed the genome-wide results using FUMA v1.3.2 23 , selecting a random sample of 10,000 UK Biobank participants of European ancestry as an LD reference dataset 24 . Variants were filtered using a P value < 5 x 10 -8 and independent genomic loci were LD-pruned based on an r 2 < 0.1. We calculated Cochrane's Q and I 2 statistics to assess whether the effect estimates for HF sentinel variants were consistent across studies 25 .
Heritability (h 2 g) estimation. To estimate the proportion of HF risk explained by common variants we estimated h 2 g on the liability scale using LDSC on the UK Biobank summary data (6,504 HF cases, 387,652 controls), assuming a population prevalence of 2.5% 26 . This approach assumes that a binary trait has an underlying continuous liability, and above a certain liability threshold an individual becomes affected. We can then estimate the genetic contribution to the continuous liability. Sample ascertainment can change the distribution of liability in the sampled individuals and needs to be adjusted for, which requires making assumptions about the population prevalence of the trait. This LD reference dataset was used for downstream summary-based analysis and for identifying SNP proxies.
Gene Mapping Analysis
Gene set enrichment analysis. A gene-based and gene-set enrichment analysis of variant associations was performed using MAGMA 27 , implemented by FUMA v1.3.2 23 . This analysis was performed using summary-level meta-analysis results. First, a gene-based association analysis to identify candidate genes associated with HF was conducted. Second, a tissue-enrichment analysis of HF associated genes was performed using gene expression data for 30 tissues from GTEx.
Finally, a gene-set enrichment analysis was performed based on pathway annotations from the Gene Ontology database 28 . For all MAGMA analyses, multiple testing was accounted for by Bonferroni correction.
Missense consequences of sentinel variants and proxies.
We queried the protein-coding consequence of the sentinel variants and proxies (r 2 > 0.8) using the Combined Annotation Dependent Depletion (CADD) score 29 , implemented using FUMA v1.3.2 23 . The CADD score integrates information from 63 distinct functional annotations into a single quantitative score, ranging from 1 to 99, based on variant rank relative to all 8.6 billion possible SNVs of the human reference genome (GRCh37). Sentinel SNPs or proxies with CADD score > 20 were identified. A 33, 34 . We queried HF sentinel variants for eQTL associations with genes located either fully or partly within a 1 megabase (Mb) upstream or downstream of the sentinel variant (referred to as cis-genes). We accounted for multiple testing by adjusting a significance threshold of P < 0.05 for the total number of SNP-cis-gene tests performed across the four heart tissue eQTL datasets (P < 4.73E-05 for a total of 1,056 SNP-gene associations). Baseline characteristics for the MAGNet study are provided in Supplementary Table 18 . We also queried sentinel HF variants for associations with cis-gene expression in blood from the eQTLGen consortium (N = 31,684) 35 . Given the large sample size, we used a stringent genome-wide significance threshold of P < 5 x 10 -8 to identify significant blood eQTLs.
Colocalisation analysis. Bayesian colocalisation analysis was performed using coloc to test whether shared associations with gene expression and heart failure risk were consistent with a single common causal variant hypothesis 36 . We tested all genes with significant cis-eQTL association by analysing all variants within a 200 kilobase window around the gene using eQTL summary data for heart tissues and whole blood, and HF summary data from present study. We set the prior probability of a SNP being associated only with gene expression, only with HF, or with both traits as 10 -4 , 10 -4 , and 10 -5 . For each gene, we report the posterior probability that the association with gene expression and HF risk is driven by a single causal variant. We consider a posterior probability of ³ 0.7 as providing evidence supporting a causal role for the gene as a mediator of HF risk.
Transcriptome-wide association analysis. We employed the S-PrediXcan method 37 implemented in the MetaXcan software (https://github.com/hakyimlab/MetaXcan) to identify genes whose predicted expression levels in heart tissue are associated with HF risk. Prediction models trained on GTExv7 heart tissue datasets were applied to the HERMES meta-analysis results. Only models that significantly predicted gene expression in the GTEx eQTL dataset (FDR <0.05) were considered. A total of 4859 genes were tested in left ventricle tissue and 4467 genes for right atrial appendage. Genes with an association P < 5.36×10−6 (0.05 / (4859 + 4467)) were considered to have gene expression profiles significantly associated with HF.
Protein quantitative trait analysis in blood. We queried both cis-and trans-protein QTL (pQTL) associations based on measures for serum proteins mapping to 3000 genes in 3,301 healthy individuals from the INTERVAL study 38 . We accounted for multiple testing by adjusting a significance threshold of P < 0.05 for the total number of tests for all variants and proteins tested (36,000 tests).
Association of HR risk loci with other phenotypes
GWAS Catalog. We queried associations (with P < 1 x 10 -5 ) of sentinel variants and proxies (r 2 > 0.6) with any trait in the NHGRI-EBI Catalog of published GWAS (accessed 21 January 2019) 39, 40 . HF-related phenotypes. We queried GWAS data for ten traits related to HF risk factors, endophenotypes and related disease traits using summary-level data from the largest available GWAS study (either publicly available or through agreement with study investigators). The following phenotypes were considered: fractional shortening (FS), left ventricular dimension (LVD) 41 , dilated cardiomyopathy (DCM); atrial fibrillation (AF) 42 , coronary artery disease (CAD) 43 , low density lipoprotein cholesterol (LDL-C) 44 , type 2 diabetes (T2D) 45 ; body mass index (BMI) 46 , systolic blood pressure (SBP), and diastolic blood pressure (DBP) 47 . For DCM, a GWAS was performed in the UKB among individuals of European ancestry with cases defined by the presence of ICD10 code I42.0 as a main/secondary diagnosis or primary/secondary cause of death with non-cases as referents, using PLINK2. Logistic regression was performed with adjustment for age, sex, genotyping array, and the first ten principal components.
UK
Hierarchical agglomerative clustering. We performed hierarchical agglomerative clustering on a locus level using the complete linkage method based on the associations with related traits as described above. Where a sentinel variant is not available in any of the other traits summary results, a common proxy is used in place of the sentinel variant. For the LPA locus, we used associations for a proxy of the more common variant (rs55730499). Dissimilarity structure was calculated using Euclidean distance based on the Z-score (beta of continuous traits or log odds of disease risk divided by standard error) of the cross-trait associations. We accounted for multiple testing at family-wise error rate of 0.05 by Bonferroni correction for the 10 traits tested per HF locus (110 tests),and considered P < 4.5e -4 (0.05 / 110) as our significance threshold for association.
Genetic correlation analysis
We estimated genetic correlation between HF and eleven risk factors using LD score regression 22 on the GWAS summary statistics for each trait: AF 42 , CAD 43 , LDL-C, high density lipoprotein cholesterol (HDL-C), triglycerides (TG) 44 , T2D 45 ; BMI 46 , SBP, DBP 47 , heart rate (HR) 48 and estimated glomerular filtration rate (eGFR) 49 .
Mendelian randomisation analysis
We performed two sample Mendelian randomisation analysis using the Generalized summary databased Mendelian randomisation (GSMR) 50 implemented in GCTA v1.91.7beta 51 . To identify independent SNP instruments for each exposure, GWAS-significant SNPs (P < 5x10 -08 ) for each risk factor were pruned (r 2 < 0.05; LD window of 10,000kb; using the UKB10K LD reference). We then estimated the causal effect of the risk factor on the disease trait according to the MR paradigm. The HEIDI test implemented in GSMR was used to detect and remove (if HEIDI p-value <0.01) variants showing horizontal pleiotropy i.e. having independent effects on both exposure and outcome, as such variants do not satisfy the underlying assumptions for valid instruments. As sensitivity analyses, we estimated the causal effects of known risk factors on HF risk other statistical methodology and software -the R package TwoSampleMR 52 was used to select independent variant instruments for the exposure using the same parameters as per the GSMR analysis (P < 5x10 -8 ; r2 <0.05; LD window of 10,000kb), except the TwoSampleMR package uses the 1000 Genomes as the LD reference. Causal estimates based on the inverse-variance weighted (IVW) 53 , MR-Egger and median weighted methods 54 were then calculated using the MendelianRandomization 55 R package. To enable comparison of MR estimates between traits, we present effect estimates corresponding to the risk of HF for a 1-standard deviation (SD) higher risk factor of interest. Where the original GWAS conducted rank based inverse normal transformation (RINT) of a trait prior to GWAS, we used the per-allele beta coefficients following RINT to approximate the equivalent values on the standardised scale, as has been conducted previously.
To determine if the causal effects of the continuous risk factors on HF were mediated via their effects on CAD or AF risk, we repeated the GSMR analysis after conditioning the HF summary statistics on CAD and AF GWAS summary statistics, as described below.
Conditional analysis. To estimate the effects of HF risk variants after adjusting for risk factors which showed a significant causal effect on HF in the MR analyses, we performed the Multi-trait Conditional and Joint Analysis (mtCOJO) on summary data, as implemented in GCTA v1.91.7beta 51 . HF summary statistics were adjusted for AF 34 , CAD 43 , LDL-C, HDL-C, triglycerides 44 , DBP, SBP 47 and BMI 46 using GWAS summary data. The UKB10K LD reference was used.
